Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Harvard Business School
AstraZeneca
Merck
Boehringer Ingelheim

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,176,211

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,176,211 protect, and when does it expire?

Patent 7,176,211 protects ORILISSA and is included in one NDA.

This patent has twenty-nine patent family members in twenty-two countries.

Summary for Patent: 7,176,211
Title:Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: ##STR00001## wherein R.sub.1a, R.sub.1b, R.sub.1c, R.sub.2a, R.sub.2b, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
Inventor(s): Guo; Zhiqiang (San Diego, CA), Chen; Yongsheng (San Diego, CA), Wu; Dongpei (San Diego, CA), Chen; Chen (San Diego, CA), Wade; Warren (San Diego, CA), Dwight; Wesley J. (San Diego, CA), Huang; Charles Q. (San Diego, CA), Tucci; Fabio C. (San Diego, CA)
Assignee: Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:11/251,085
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,176,211

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie Inc ORILISSA elagolix sodium TABLET;ORAL 210450-001 Jul 23, 2018 RX Yes No   Start Trial   Start Trial MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS   Start Trial
Abbvie Inc ORILISSA elagolix sodium TABLET;ORAL 210450-002 Jul 23, 2018 RX Yes Yes   Start Trial   Start Trial MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,176,211

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 407679   Start Trial
Australia 2004257639   Start Trial
Brazil PI0412314   Start Trial
Canada 2531508   Start Trial
China 100424078   Start Trial
China 1819829   Start Trial
Cyprus 1108656   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Mallinckrodt
Baxter
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.